Viewing data from:

FIORICET W/ CODEINE

NDA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE | N020232 | ACTAVIS LABORATORIES UT INC

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$0.8057

per ea

Lowest NADAC/Unit

$0.8057

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00591322001BUTALBITAL-ACETAMINOPHEN-CAFFEINE-CODEINE 50-325-40-30 MG CP	$0.8057	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (1 FSS, 1 Big4)

Lowest Price

$9.56

Highest Price

$68.25

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00591-3220-01COD 30MG/APAP 325MG/BUTALBITAL 50MG/CAFN 40MG	$68.25	FSS	Teva Pharmaceuticals USA, Inc.	04/30/2026
00591-3220-01COD 30MG/APAP 325MG/BUTALBITAL 50MG/CAFN 40MG	$9.56	Big4	Teva Pharmaceuticals USA, Inc.	04/30/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Approval Letters

14 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (1)

#001 — 325MG;50MG;40MG;30MG

RLDAB

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Jul 30, 1992

No patent or exclusivity listings for this strength.